AAVantgarde Bio
PrivateLast Round
Series B
Nov 3, 2025
Total Funding Raised
$210.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
AAVantgarde Bio is a biotechnology company that develops gene therapies for inherited retinal disorders, utilizing proprietary Adeno-Associated Viral (AAV) vector platforms to deliver large genes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AAVantgarde Bio Comparables
Compare AAVantgarde Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SpliceBio | 89% | |
| Atsena Therapeutics | 86% | |
| Opus Genetics | 79% | |
AAVantgarde Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 3, 2025 | ||||
| Series A | Jun 6, 2023 | ||||
| Seed | Jun 30, 2021 | ||||
| Seed | Jun 1, 2021 |
Key People
Founding team and executive leadership
AAVantgarde Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series A |
| Sixty Degree Capital | Series B |
| XGEN Venture | Series B |
| Forbion | Series A, Series B |
| Neva SGR | Series B |
| Athos KG | Series B |
| Accomplice | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 12, 2026
Will present at the 44th Annual J.P. Morgan Healthcare Conference.
- Nov 3, 2025
$141M round completed.
AAVantgarde Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AAVantgarde Bio's valuation, stock price, and market status.